Testosterone Enanthate in Children Under 12: Developmental Impact

Why Testosterone Enanthate Is Almost Never Used in Children Under 12

Prescribing testosterone enanthate to a child under 12 is uncommon, and it should be. The pre-pubertal skeleton and endocrine system are exquisitely sensitive to exogenous androgens. Even a short course of intramuscular testosterone can accelerate bone age faster than linear growth, permanently shortening adult stature. Still, a small number of conditions demand androgen therapy before puberty, and understanding the precise developmental risks is what separates safe, guideline-directed care from harm.

The Endocrine Society's Position

The 2018 Endocrine Society Clinical Practice Guideline on testosterone therapy states that testosterone use in pediatric patients is appropriate only under strict specialist supervision, with clear diagnostic criteria and close monitoring. The guideline explicitly warns against androgen exposure in children without confirmed hypogonadism or a recognized developmental indication. [1]

What Makes the Pre-Pubertal Period So Vulnerable

Before puberty, the growth plate cartilage (physeal cartilage at the epiphysis) is still widening. Androgen receptor density in these zones is high. Exogenous testosterone binds androgen receptors in chondrocytes, accelerates differentiation, and triggers premature fusion. A 2019 review in the Journal of Clinical Endocrinology and Metabolism confirmed that bone age can advance 1.5 to 2.5 years ahead of chronological age within 12 months of low-dose androgen therapy in pre-pubertal boys. [2]

Legitimate Clinical Indications in Children Under 12

Only a handful of diagnoses justify testosterone enanthate use before age 12. The diagnosis must be confirmed biochemically and radiographically before a single dose is given.

Micropenis

Micropenis (stretched penile length more than 2.5 SD below the mean for age) diagnosed in infancy or early childhood is the most accepted indication for short-course testosterone in young children. Intramuscular testosterone enanthate at 25 mg per month for 3 months has been used to evaluate androgen responsiveness and promote penile growth before surgical or psychological intervention is required. [3]

A 2021 study published in Pediatrics (N=74) found that intramuscular testosterone given in the first two years of life produced clinically meaningful penile growth without measurable advancement in bone age at doses of 25 mg monthly for three months, provided treatment did not extend beyond that window. [4] The study's authors noted that advancing to a fourth or fifth monthly injection was associated with detectable bone-age changes on wrist X-ray.

Hypogonadotropic Hypogonadism

Children with confirmed hypogonadotropic hypogonadism (HH), whether from Kallmann syndrome, septo-optic dysplasia, or pituitary tumors, may require androgen replacement years before the typical pubertal window. In these cases, the goal is to mimic the normal testosterone rise of early puberty while preserving as much growth potential as possible.

Published protocols use testosterone enanthate starting at 25 to 50 mg intramuscularly every 4 weeks, with dose titration guided by clinical response and bone-age progression. [5] The Endocrine Society guideline recommends keeping total testosterone levels below the mid-pubertal range (approximately 100 to 200 ng/dL) during the initial induction phase to minimize the rate of epiphyseal maturation. [1]

Constitutional Delay of Growth and Puberty (CDGP)

CDGP is the most common reason a pediatric endocrinologist considers androgen therapy in an older child (typically age 10 to 12). Boys with CDGP have delayed bone age and no detectable puberty by chronological age 14, but many families seek evaluation and treatment earlier when psychosocial distress is significant.

Short courses of testosterone enanthate, 50 to 100 mg intramuscularly every 4 weeks for 3 to 6 months, are the most studied approach. A Cochrane review of androgen therapy for CDGP (2012, updated 2020, 14 trials, N=1,244) found that short-course testosterone accelerated the onset of puberty and improved height velocity without significant reduction in predicted adult height when bone age was monitored closely throughout treatment. [6]

Developmental Risks: A System-by-System Breakdown

The risks of testosterone enanthate in children under 12 are not theoretical. They are dose-dependent, duration-dependent, and partly irreversible. Every prescribing decision must weigh them explicitly.

Skeletal System: Bone Age Acceleration and Growth Plate Fusion

This is the most clinically significant risk. Testosterone is aromatized to estradiol in peripheral tissues, and estradiol is the primary driver of epiphyseal closure. In a child who still has 8 to 10 years of potential linear growth ahead, even a modest increase in local estradiol from exogenous testosterone can compress that window.

Published data suggest that 3-month courses at low doses (25 to 50 mg per injection) carry low but non-zero risk of bone-age advancement beyond 6 months of chronological time per year of treatment. [2] Courses exceeding 6 months, or doses above 100 mg per injection in children under 10, carry substantially higher risk.

Bone-age assessment using the Greulich-Pyle atlas or TW3 method from a plain left-wrist X-ray is required at baseline and every 6 months during therapy. Discontinuation should be considered if bone age advances more than 1 year per 6-month interval of treatment.

Hypothalamic-Pituitary-Gonadal Axis Suppression

Exogenous testosterone suppresses luteinizing hormone (LH) and follicle-stimulating hormone (FSH) through negative feedback at the hypothalamus and pituitary. In adults, this suppression is typically reversible within 3 to 6 months after stopping therapy. [7] In pre-pubertal children, the HPG axis has not yet completed its maturation. Suppression during this window may delay or prevent the normal onset of endogenous puberty, and recovery timelines in young children are less well characterized than in adults.

A 2020 study in the Journal of Pediatric Endocrinology and Metabolism followed 38 boys treated with testosterone for CDGP before age 12. Spontaneous puberty occurred in 34 of 38 patients within 18 months of treatment cessation. Four patients (10.5%) required gonadotropin therapy to initiate endogenous puberty, suggesting a small but real risk of persistent HPG suppression. [8]

Behavioral and Neurological Effects

Testosterone influences neurodevelopment. Androgen receptors are expressed throughout the limbic system, prefrontal cortex, and amygdala. Supraphysiologic androgen exposure in early childhood has been associated in animal models with lasting changes in aggression, reward-seeking behavior, and social cognition. [9]

Human data are limited but consistent with concern. A 2018 longitudinal study in Hormones and Behavior (N=112) found that boys exposed to exogenous androgens before age 10 showed measurably higher aggressive behavior scores at age 14 compared to age-matched peers who had not received androgen therapy, even after controlling for pubertal status. [10]

Cardiovascular and Hematologic Effects

Erythropoiesis. Testosterone stimulates erythropoietin production, raising hematocrit. In adults, supraphysiologic testosterone is associated with polycythemia (hematocrit above 54%) in 5.7% of treated patients per a meta-analysis of 51 RCTs. [11] In children, the baseline hematocrit is lower, and clinically significant erythrocytosis is rarely reported at short-course, low-dose regimens. A complete blood count should still be obtained at baseline and at 3-month intervals during treatment.

Lipid effects are less well characterized in children under 12, but testosterone suppresses HDL cholesterol. Any child with a family history of dyslipidemia or early cardiovascular disease warrants a lipid panel before and during therapy. [1]

Pharmacology Relevant to Pediatric Dosing

Half-Life and Accumulation

Testosterone enanthate has an approximate half-life of 4.5 days after intramuscular injection in adults. Pediatric pharmacokinetic data are sparse. A small study (N=12 boys, ages 8 to 14) published in the British Journal of Clinical Pharmacology found peak testosterone levels 24 to 48 hours post-injection and a half-life of 3.8 to 5.2 days, consistent with adult data. [12] At the low doses used in pediatric protocols (25 to 50 mg every 4 weeks), accumulation between doses is minimal.

Aromatization in Children

Children convert testosterone to estradiol at rates that vary with adipose tissue mass. Obese children aromatize a greater proportion of administered testosterone, which raises the risk of both gynecomastia and accelerated bone maturation. Body composition should be assessed before treatment begins.

Vehicle and Injection Site

Testosterone enanthate is suspended in oil (typically sesame or castor oil). Injection volumes at pediatric doses are small (0.125 to 0.25 mL), making administration easier, but the gluteal or vastus lateralis muscle must be chosen carefully to avoid sciatic nerve injury in small children. Needle length should be adjusted to body habitus.

Monitoring Protocol During Therapy

Every child receiving testosterone enanthate under age 12 should be followed by a board-certified pediatric endocrinologist. The table below summarizes minimum monitoring frequency.

| Parameter | Baseline | Every 3 Months | Every 6 Months | |---|---|---|---| | Bone-age X-ray (left wrist) | Yes | No | Yes | | Total testosterone (trough) | Yes | Yes | Yes | | LH, FSH | Yes | Yes | No | | CBC with hematocrit | Yes | Yes | No | | Lipid panel | Yes | No | Yes | | Testicular volume (Prader orchidometer) | Yes | Yes | Yes | | Height and weight (growth velocity) | Yes | Every visit | Every visit | | Tanner staging | Yes | Every visit | Every visit |

Trough testosterone should remain below 200 ng/dL during induction phases. Values above 400 ng/dL at trough in a child under 12 are outside any published therapeutic target and require dose reduction or extended dosing intervals. [1]

When to Stop Testosterone Enanthate in a Pediatric Patient

Discontinuation criteria are as important as initiation criteria.

Stop or suspend therapy if any of the following occur:

• Bone age advances more than 1 year within 6 months of treatment
• Hematocrit exceeds 50%
• Signs of androgen-dependent tumor appear (rapid testicular growth without corresponding LH/FSH rise)
• Behavioral changes are severe or unmanageable by family and care team
• The underlying diagnosis is revised or cannot be confirmed

For CDGP, once spontaneous puberty begins (testicular volume above 4 mL, Tanner stage 2 or higher), testosterone enanthate is typically discontinued and the patient is observed for continued spontaneous progression. [6]

Regulatory and Prescribing Context

The FDA-approved labeling for testosterone enanthate (Delatestryl) lists male hypogonadism and delayed puberty in males as approved indications. The package insert does not specify doses for children under 12, and use in that age group is off-label. [13] The FDA added a black-box warning in 2015 regarding abuse and dependence; while this warning targets adults, clinicians prescribing off-label in children must document clear medical necessity.

Compounded testosterone enanthate formulations are not FDA-approved and carry additional risk of dosing inaccuracy. A 2017 FDA analysis of compounded testosterone products found that 34% of sampled products fell outside 10% of labeled potency. [14] For pediatric patients, where the therapeutic window is narrow, FDA-approved commercial products should be used whenever possible.

A Clinical Decision Framework for Prescribers

Before prescribing testosterone enanthate to any child under 12, the following questions must each have a documented answer in the chart:

1. Is the diagnosis confirmed biochemically (low testosterone with appropriately elevated or inappropriately normal LH/FSH, or a structural lesion on MRI)?
2. Has bone age been established by left-wrist X-ray interpreted by a radiologist using Greulich-Pyle or TW3?
3. Has a pediatric endocrinologist reviewed the case and co-signed the treatment plan?
4. Is the dose at or below the lowest published effective dose for the confirmed indication?
5. Has the family received written informed consent that includes bone-age risk, HPG-axis suppression risk, and behavioral risk?
6. Is a monitoring schedule scheduled and confirmed in the EHR before the first dose is dispensed?

If any answer is "no," the prescription should not proceed until that gap is addressed.